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ABSTRACT Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis
(SSc) and is the leading cause of death in SSc. Our objective was to gain insight into the progression of
SSc-associated ILD (SSc-ILD). Using data from longitudinal clinical trials and observational studies, we
assessed definitions and patterns of progression, risk factors for progression, and implications for
treatment.
SSc-ILD progression was commonly defined as exceeding specific thresholds of lung function worsening
and/or increasing radiographic involvement. One definition used in several studies is decline in forced vital
capacity (FVC) of ⩾10%, or ⩾5–10% plus a decline in diffusing capacity of the lung for carbon monoxide
⩾15%. Based on these criteria, 20–30% of patients in observational cohorts develop progressive ILD,
starting early in the disease course and progressing at a highly variable rate.
Risk factors such as age, FVC, extent of fibrosis and presence of anti-topoisomerase I antibodies can
help predict progression of SSc-ILD, though composite risk scores may offer greater predictive power.
Whilst the variability of the disease course in SSc-ILD makes risk stratification of patients challenging, the
decision to initiate, change or stop treatment should be based on a combination of the current disease
state and the speed of progression.
Introduction
Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc), affecting
approximately 50% of all patients with SSc [1–3], though prevalence estimates vary depending on the
diagnostic method used. Studies published in the last decade have shown that ILD is the leading cause of
death in SSc, representing an estimated 17–35% of all SSc-related deaths [4–6]. Accurately assessing and
defining disease progression in SSc-ILD could help identify patients at risk and help guide disease
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management. In this review, we assess the progression of ILD in SSc using data from clinical trials of
investigational new drugs for SSc-ILD as well as observational cohort studies. The four areas of focus are:
1) definitions of progression; 2) patterns of progression; 3) single and composite risk factors for
progression; and 4) implications for treatment. A video abstract summarising this review article is available
at: www.globalmedcomms.com/respiratory/Vonk/SSc-ILD_Disease_Course_Review
Definitions of progression in SSc-ILD
Although there is no consistent definition of progression in the SSc-ILD literature, attempts have been
made to define progression based on changes in pulmonary function (forced vital capacity (FVC) and
diffusing capacity of the lung for carbon monoxide (DLCO)). One definition of clinically meaningful
progression that has informed several observational studies and clinical trials is a ⩾10% relative decline in
FVC, or ⩾5% to <10% relative decline in FVC together with ⩾15% relative decline in DLCO [7–9]. This is
consistent with definitions used in some studies of idiopathic pulmonary fibrosis (IPF) [10–12]. It is also
comparable to a recent study of chronic fibrosing ILDs with a progressive phenotype, in which patients
were required to have the following: a ⩾10% relative decline in FVC % predicted, or ⩾5% to <10% relative
decline in FVC % pred and worsening respiratory symptoms/increased extent of fibrosis on
high-resolution computed tomography (HRCT), or worsening of respiratory symptoms and increased
extent of fibrosis [13]. A recent position paper also suggests that the chronic fibrosing ILD with
progressive phenotype is defined by disease progression despite treatment and should take into
consideration pulmonary function tests (PFTs), HRCT and patient symptoms [14]; however, an
internationally accepted definition has not been agreed. Since decline in lung function in SSc-ILD is
typically slower and less predictable than in IPF (survival 2–5 years), more sensitive cut-off criteria to
define progression may be needed for SSc-ILD. Indeed, using 12 months of data from the Scleroderma
Lung Study (SLS) I and II (n=300), one post-hoc analysis defined a change (±) in FVC of 3.0% as the
minimum clinically important difference for progression, when interpreted in the light of changes in
dyspnoea index score and self-reported patient outcomes at 12 months [15].
Clinically meaningful progression may be more reliably defined by combining several clinical measures.
Several authors have proposed criteria for progression of SSc-ILD based on a combination of pulmonary
function measures with radiographic extent of fibrosis on HRCT [6–9, 16–22]. Although extent of ILD on
HRCT [16, 17] can indicate disease progression in SSc-ILD (especially when pulmonary function is
unclear), conducting regular HRCT scans in clinical practice may not be feasible, and there is no
consensus about how often patients should undergo a scan. In the future, advances in artificial intelligence
may significantly modify the practice of radiology, increasing its accuracy in detecting structural changes [23].
In a series of evidence-based consensus statements on the diagnosis and management of SSc-ILD,
developed by a panel of 27 Europe-based physicians with expertise in SSc-ILD, 100% of participants
agreed that FVC % pred can indicate disease progression in SSc-ILD, and that lung function is an effective
post-diagnostic, long-term, follow-up measurement for assessing disease progression in SSc-ILD [18].
However, specific thresholds in FVC were not given as part of these consensus statements. Diagnostic tools
for identifying progression were defined as measurements of FVC and DLCO, HRCT to assess changes in
extent or pattern of fibrosis, and detection of worsening symptoms [18].
Patterns of disease progression in SSc-ILD
Pulmonary involvement typically occurs within the first few years of onset of SSc [24–26]. Indeed, in a
minority of patients (∼4%), ILD is the first manifestation of SSc [27, 28]. Unlike the progressive fibrosing
disease course of IPF, which has been well characterised [29], the course of SSc-ILD is characterised by a
high degree of heterogeneity. Lung function deterioration may occur both early and late in the disease
course [26, 30], and patients could be classified as having rapid or slow disease progression, disease
stability or improvement. This status can change during the disease course of SSc-ILD, and this
heterogeneity reflects the need for ongoing patient monitoring [30].
Developing a better understanding of the natural variability in the disease course of SSc-ILD may allow for
risk stratification of patients and a more tailored approach to treatment and clinical management. In this
section, we explore the variability in the disease course of SSc-ILD by looking at data from: 1) clinical
trials (table 1), which typically have restrictive inclusion and exclusion criteria; and 2) observational
cohorts, such as single-centre or multicentre databases, which recruit a wider cross-section of patients
receiving various therapeutic regimens.
Clinical trials in SSc and SSc-ILD
Clinical trials provide well-controlled longitudinal data in well-characterised SSc cohorts and enable
comparison of disease progression between treatment and non-treatment arms. One approach to assessing
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TABLE 1 Progression in clinical trials of systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Study [ref.] Duration Sample size Treatment
centres n
Inclusion criteria Measures of progression
FVC HRCT Deaths




13 >18 years of age
dcSSc or lcSSc
Evidence of acute alveolitis on BAL
examination or ground-glass opacity on
HRCT
Onset of first (non-Raynaud) SSc symptom
within 7 years
FVC % pred 45–85%
Grade 2 exertional dyspnoea on Mahler
Dyspnoea Index
Change in mean


















14 18–75 years of age
dcSSc or lcSSc
FVC % pred 45–85%
Any ground-glass opacity on HRCT (whether
associated with reticulations or not)
Onset of first (non-Raynaud) SSc symptom
within 7 years
Grade 2 exertional dyspnoea on Mahler
Dyspnoea Index
Change in mean
±SE FVC % pred:
CYC: +3.0±1.2%
MMF: +3.3±1.1%























35 >18 years of age
Diagnosis of SSc as per 1980 ACR criteria
Onset of first (non-Raynaud) SSc symptom
within 5 years
mRSS score 15–40
Active disease (defined by pre-specified
mRSS/biomarker criteria)
Change in mean







0.01) at 96 weeks
TCZ
−0.02% (−0.04–
0.00) at 48 weeks
−0.01% (−0.03–
0.02) at 96 weeks
























Study [ref.] Duration Sample size Treatment
centres n
Inclusion criteria Measures of progression
FVC HRCT Deaths







83 Diagnosis of SSc as per ACR/EULAR
criteria, meeting criteria for active disease









Change in whole lung
scores:
QLF in double-blind















1 18–60 years of age
dcSSc, as per ACR classification criteria
Scl-70 antibody positivity
ILD confirmed by HRCT and PFTs (FVC % pred
45–85%)
Onset of first (non-Raynaud) SSc symptom
within 3 years






Not recorded RTX: 1/30
CYC: 1/30





195 >18 years of age
SSc as per ACR/EULAR classification criteria
Onset of first (non-Raynaud) SSc symptom
within 7 years
ILD confirmed by >10% fibrosis on HRCT
within 12 months of screening
FVC % pred >40%
DLCO % pred 30–89%
Annual rate±SE of
















SSc as per ACR/EULAR criteria, and dcSSc
defined as per early SSc criteria [39]
Disease duration of ⩽36 months (time from
the first non-Rayaud symptom)































Study [ref.] Duration Sample size Treatment
centres n
Inclusion criteria Measures of progression
FVC HRCT Deaths




1 <60 years of age
dcSSc (mRSS score >14 and cutaneous
involvement proximal to the elbow or knee)
Internal organ involvement: DLCO % pred
<80%; decline in FVC % pred >10% within
past 12 months; lung fibrosis or
ground-glass opacities on HRCT; ECG or GI
involvement
Change in mean


















29 18–65 years of age
dcSSc as per ACR criteria
Maximum disease duration of 4 years
mRSS score >15
Involvement of heart, lungs or kidneys
Prior treatment with CYC allowed up to a
cumulative dose of 5 g intravenously, or up
to 2 mg·kg−1 body weight orally for
3 months
Change in mean




Not recorded HR for overall survival:










26 18–69 years of age
SSc as per ACR criteria
Maximum disease duration of 5 years
Active ILD (determined by BAL composition or
chest CT)
FVC or DLCO <70% pred renal involvement
Not recorded Change from baseline










mortality at 54 months:
CYC: 0/39
HSCT: 1/36
FVC: forced vital capacity; HRCT: high-resolution computed tomography; SLS: Scleroderma Lung Study; RTX: rituximab; CYC: cyclophosphamide; dcSSc: diffuse cutaneous SSc; lcSSc:
limited cutaneous SSc; BAL: bronchoalveolar lavage; MMF: mycophenolate mofetil; QLF: quantitative lung fibrosis; QILD: quantitative ILD; TCZ: tocilizumab; ACR: American College of
Rheumatology; mRSS: modified Rodnan skin score; EULAR: European League Against Rheumatism; PFT: pulmonary function test; NYHA: New York Heart Association; DLCO: diffusing
capacity for carbon monoxide; LSM: least squares mean; HSCT: haematopoietic stem cell transplantation; GI: gastrointestinal; CT: computed tomography. #: after 10 years of follow-up,






















disease progression is to evaluate changes in end-points such as FVC % pred over time, which can indicate
whether patients have declined, stabilised, or even improved in terms of their lung function over a given
time period. The placebo arms of clinical trials can provide important information about the natural
history of ILD and baseline predictors of progression, particularly in the absence of any background
therapy. In this opening section, we assess changes in FVC % pred and other key end-points in clinical
trials of investigational drugs for SSc and SSc-ILD.
Cyclophosphamide and mycophenolate mofetil
The treatment of SSc-ILD has, until recent years, focused on immunosuppressive therapies, in particular
cyclophosphamide (CYC) and mycophenolate mofetil (MMF), based on the results of two pivotal clinical
trials: SLS I and II [31, 33]. These studies recruited patients with evidence of active pulmonary
inflammation, defined either by the presence of alveolitis on bronchoalveolar lavage and/or any
ground-glass opacity on HRCT (SLS I), or by any ground-glass opacity on HRCT (SLS II) [31, 33] and the
results are summarised in table 1. In the phase III SLS I, patients received either oral CYC or placebo for
12 months, and were then followed up for a further 12 months without therapy [31]. In total, 26% of
patients in the placebo arm had improved FVC % pred at 12 months follow-up; 14% of patients had a
decline in FVC % pred of 5–10%, and 12% had a decline in FVC % pred >10% during the 12-month
follow-up [44, 45]. There was also variability in disease behaviour in the treatment arm, with 49% of
patients showing improved FVC % pred after 12 months, 13% of patients showing a decline of 5–10%, and
7% showing a decline of >10% during the 12-month follow-up [31, 44]. In a separate, placebo-controlled
study of intravenously administered CYC, mean±SD FVC % pred in the placebo arm was 81.0±18.8% at
baseline and 78.0±21.6% at week 52 follow-up [46].
The phase II SLS II trial compared the efficacy and safety of 12 months of oral CYC (followed by
12 months of placebo) and 24 months of MMF [33]. Overall, 64.7% of patients in the CYC arm had
improved FVC % pred at 24 months, 5% of patients had a decline of 5–10%, and 2% had a decline of
>10% during the 24 months. In the MMF arm, 71.7% had improved FVC % pred at 24 months, 5% of
patients had a decline of 5–10%, and 2% had a decline of >10% during the 24 months [45]. In an analysis
of HRCT outcomes in SLS II, changes in quantitative lung fibrosis score and quantitative ILD score were
defined as worse (>2%), stable (−2–2%) and better (>−2%). Using the quantitative ILD score, 32% versus
26% had worse fibrosis, 11% versus 18% had stable fibrosis, and 57% versus 56% had better fibrosis in the
CYC and MMF arms, respectively, at the same time-point [17].
Tocilizumab
In studies of tocilizumab for the treatment of SSc, the primary focus was skin changes in patients with
early diffuse cutaneous SSc (dcSSc) and not SSc-ILD, therefore change in FVC was an exploratory
end-point. The phase II faSScinate [34] and phase III focuSSced [35] studies were enriched for patients
with evidence of active systemic inflammation, e.g. elevation of the inflammatory mediator C-reactive
protein (CRP). In the phase II faSScinate study, the mean (95% CI) change in FVC % pred in the placebo
arm was −0.06% (−0.10–−0.03; n=32) during an initial 48-week double-blind period, and −0.03%
(−0.07–0.01; n=25) after a subsequent 48-week extension period in which patients received open-label
tocilizumab [34]. In the phase III focuSSced study, the decline in median (95% CI) FVC % pred over
48 weeks was 3.9% (−4.8–−1.6) in the placebo arm, and 0.6% (−2.4–−0.9) in the tocilizumab arm [35,
47]. These studies of tocilizumab, which focused on skin-related outcomes in dcSSc but assessed FVC as
an exploratory end-point, highlight that FVC decline can occur despite normal lung function at baseline
(>80% FVC % pred in both studies), with 3–4% loss of FVC % pred in the placebo arm after 1 year [34,
47, 48]. In addition, these studies provide some evidence that tocilizumab could play a role in preventing
progression of ILD in patients with early dcSSc with inflammatory features.
Rituximab
In one study conducted in patients with SSc-ILD, the effects of rituximab in slowing lung function decline
were compared with those of CYC (standard therapy) over 6 months. In the rituximab arm (n=30), mean
±SD FVC % pred was 61.3±11.3% at baseline and 67.5±13.6% at 6 months, equating to an increase of 6.2%.
In the CYC arm (n=30), the equivalent values were 59.3±13.0% at baseline and 58.0±11.2% at 6 months
[36], equating to a decrease of 1.3%. Other studies are ongoing, such as RECITAL, a UK-based,
multicentre, prospective, randomised, double-blind, double-dummy trial comparing rituximab with CYC
(administered over a 20-week period) in patients with severe, progressive SSc-ILD, idiopathic inflammatory
myositis or mixed connective tissue disease. The primary end-point is absolute rate of change in FVC after
24 weeks, and patients will be followed up for 48 weeks from the first dose [49].
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Nintedanib
The tyrosine kinase inhibitor nintedanib was approved by the US Food and Drug Administration in 2019,
and subsequently by the European Medicines Agency in 2020, to slow the rate of decline in lung function
in patients with SSc-ILD [50, 51]. In the large-scale phase III SENSCIS trial, in which 52 weeks of
twice-daily nintedanib was compared with placebo, ILD was identified on the basis of >10% fibrosis on
HRCT, with FVC % pred >40% and DLCO predicted 30–89% (patients with both dcSSc and limited
cutaneous SSc (lcSSc) were included). In the placebo arm, patients had a median (interquartile range)
disease duration of 3.5 (0.4–7.2) years since the onset of first non-Raynaud’s symptom. At baseline, 48.6%
of patients were receiving MMF, and mean±SD FVC % pred was 72.7±16.6%. The mean±SE annual rate of
decline in FVC % pred during 52 weeks of follow-up in the placebo arm was 2.6±0.4% [37]. Therefore, of
studies with placebo arms that may include patients taking standard of care treatments, both SLS I and
SENSCIS had a mean decline in FVC % pred of 2.6% at 12 months/52 weeks [31, 37].
In the placebo arms in the subgroup analyses of SENSCIS, numerically greater annual rates of decline in
FVC have been reported in patients with the following characteristics at baseline: dcSSc (versus lcSSc) [52];
onset of first non-Raynaud’s symptom <3 years [53]; elevated CRP; and higher modified Rodnan skin
score [54, 55]. These data reflect a heterogeneous population with subgroups of patients having different
lung function declines within a year, as expected in a disease with a variable course.
Pirfenidone
Pirfenidone has been investigated in a phase II study of patients with SSc and was found to have an
acceptable tolerability profile, including in combination with MMF [56]. The efficacy and safety of MMF
in combination with either pirfenidone or placebo are currently being investigated in SLS III, a
double-blind, parallel-group, randomised, placebo-controlled trial in patients with SSc-ILD (use of CYC,
MMF, azathioprine, or other oral (or short half-life) disease-modifying antirheumatic drugs for ⩽6 months
is permitted within the year prior to screening). Completion is scheduled for March 2022 [57].
Abatacept
The safety and efficacy of abatacept were evaluated in a phase II study of patients with early dcSSc,
focusing on skin improvement [38]. Abatacept was well tolerated but changes in modified Rodnan skin
score were not significant. In the placebo arm, there was a 4.1% decline in FVC % pred at 12 months.
Autologous haematopoietic stem cell transplantation
Haematopoietic stem cell transplantation has been investigated in phase II and III trials in patients with
SSc. Key inclusion criteria were dcSSc (excluding Scleroderma: Cyclophosphamide or Transplantation),
disease duration of <5 years and presence of internal organ involvement. Baseline patient FVC % pred
ranged from 62% to 82% [40–42]. The phase II ASSIST and phase III ASTIS trials compared autologous
haematopoietic stem cell transplantation with CYC in patients with early dcSSc. Table 1 contains
information on different measurements of disease progression in these studies.
Observational cohorts
Information about the natural disease course of SSc-ILD is also available from observational cohorts.
Observational studies can reveal a more diverse and representative range of disease patterns over time than
clinical trials because they typically have greater study durations, providing a more long-term view of
disease progression. They also include a more heterogeneous group of patients that more closely reflect
real clinical practice because they are not limited by restrictive inclusion criteria. One of the largest
databases of patients with SSc is the European Scleroderma Trials and Research (EUSTAR) group, which
contains over 15000 patients with SSc [58]. In an analysis of data from 826 patients with SSc, radiographic
evidence of ILD and serial PFTs in the EUSTAR database from 2010 onwards, changes in FVC % pred
were evaluated over 12±3 months. In total, 27% of patients showed progressive ILD over the 12-month
period: 12% had significant progression (decline in FVC % pred >10%, or decline in FVC % pred 5–10%
together with DLCO % pred ⩾15%), and 15% had moderate progression (decline in FVC % pred 5–10%,
but without a decline in DLCO % pred ⩾15%) [30]. These data are consistent with those observed in SLS I,
in which 12% of patients had a decline in FVC % pred >10% during the 12-month period. During the
mean 5-year period of evaluation, ⩾3 FVC values were available for 535 (65%) patients in the EUSTAR
database, allowing for long-term assessment of the overall disease course. Of the 200 patients who showed
an overall decline in lung function during the 5-year period, 58% had a slow pattern of lung function
decline, i.e. more periods of stability or improvement than decline. One (34%) in three patients had a slow
pattern of lung function decline, but with more periods of decline than stability or improvement, and only
8% of patients had a rapid pattern of lung function decline, i.e. several consecutive episodes of FVC
decline and no periods of stability or improvement [30]. These data indicate that patterns of progression
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in SSc-ILD are highly variable, and that the majority of patients who experience progression have both
progressive and stable periods of disease within an overall long-term trajectory of decline. The overall
proportion of patients who had disease progression in this study (27%) is consistent with data from a UK
cohort of patients with SSc-ILD, in which 21–32% of patients showed a progressive decline in lung
function during a 12-month period (decline in FVC % pred >10% or decline in DLCO % pred ⩾15%) [8].
National SSc databases have been established in countries such as Germany [59], the UK [8, 60], the USA
[61], Australia [62], Canada [63], Norway [2], Singapore [64] and France [65]. However, the availability of
long-term, follow-up data varies by country. In one US cohort of patients with SSc retrospectively assessed
for up to 12 years, patterns of progression were highly variable (up to seven categories of progression were
identified), consistent with a EUSTAR database study [30]. Most patients (85%) had slowly improving or
stable trajectories (⩽1% increase in FVC per year), with 15% of patients declining at rates of 2–3% FVC
per year. In this study, CYC therapy was associated with significant improvement in the group with low
baseline FVC and fast decline in FVC pattern (p=0.027), and there was a trend towards FVC deterioration
in the group with low baseline FVC and stable FVC pattern (p=0.06), indicating the presence of distinct
patient groups [61]. In a Canadian, single-centre, observational study of 171 patients with SSc-ILD,
subgroups with different phenotypes were described based on lung progression. To account for survival
bias, patients were categorised into three prognostic groups based on their length of survival. Patients with
short-term mortality (deceased <4 years) had a higher annual rate of decline in FVC % pred in the first
2 years than those with medium-term (deceased 4–8 years) or long-term (alive at 8 years) mortality
(annual rate of decline −9.99% (95% CI −10.53–−9.46) versus −3.04% (−3.10–−2.98) versus −1.69%
(−1.71–−1.67), respectively; n=171), highlighting the prognostic relevance of FVC decline in the early
stages of the disease (up to 2 years post-diagnosis) [63]. In this study, no association was found between
previous and current change in FVC in any given year, i.e. FVC change in a previous year was not a
statistically significant predictor of FVC change in the subsequent year [63], again highlighting the high
degree of heterogeneity and unpredictability in the disease course of SSc-ILD.
Risk factors for development and progression of SSc-ILD
SSc-ILD is a heterogeneous disease with varying rates of disease progression depending on the patient
population. Several demographic factors are associated with the presence of ILD in SSc. For example,
males with SSc more frequently develop ILD (RR 1.24 (95% CI 1.01–1.52)) and have an increased risk of
ILD-associated mortality compared with females with SSc (HR 1.58 (95% CI 1.26–1.98)) [66]. In one
large-scale analysis of SSc-related death in 11193 patients from the EUSTAR database, respiratory causes
(including ILD and pulmonary hypertension) were responsible for 17% of deaths over a median 2.3 years
of follow-up, and men had a four-fold higher rate of death from respiratory diseases compared with the
general population [5]. Ethnicity is also a predisposing factor for the development of ILD. In a
multi-ethnic observational study of 1005 patients with SSc, ILD more frequently occurred in patients of
Afro-Caribbean (53%; n=58) ethnicity compared with patients of European (31%; n=745), South Asian
(46%; n=70), East Asian (41%; n=80), Hispanic (37%; n=30), Arab (33%; n=9), North American
Indigenous (44%; n=7) or Persian (17%; n=6) ethnicities (p=0.007) [67]. In another multi-ethnic
observational study of 572 patients with SSc, ILD was diagnosed earlier in patients of Chinese descent
(median (range) 0.3 (−4.9–9.0) years)) compared with patients of European descent (median (range) 1.8
(−10.0–28.6) years; p=0.056), with similar median trough FVC in both groups (65% and 71% pred,
respectively) [68]. In a EUSTAR study, Asian and black patients with SSc were more likely to have reduced
FVC than white patients [69]. Other published risk factors for developing ILD include higher baseline skin
score, dcSSc (versus lcSSc), dcSSc with an inflammatory skin phenotype, and particularly anti-
topoisomerase I antibody positivity [37, 70–72]. In patients with SSc-ILD specifically, some studies have
shown that PFT values, HRCT patterns and other factors in the early stages of the disease are correlated
with long-term outcomes [2, 4, 5, 30, 71, 73–79]. In particular, low FVC seems to be strongly associated
with faster disease progression as it was the most frequent risk factor in these studies (table 2).
Composite risk scores in SSc-ILD
Because single risk factors may not have sufficient power to identify patients with SSc-ILD at risk of
progression, scores using a combination of clinical and laboratory parameters may be needed. For
example, GOH et al. [60] developed a limited/extensive disease staging system for SSc-ILD using a
combination of HRCT and PFT data. Disease was classified as limited (<20% fibrosis) or extensive (>20%
fibrosis) using semi-quantitative HRCT. For patients with indeterminate disease by HRCT, a threshold of
FVC 70% pred was then used to classify the remaining patients as having limited or extensive disease [60].
In a separate study by GOH et al. [8], the most accurate predictor of mortality was a relative annual decline
in FVC ⩾10%, or a relative decline in FVC of 5–9% together with a relative decline in DLCO ⩾15% [8]. In
a SPAR (SPO2 and ARthritis) model, oxygen desaturation and history of arthritis were independent
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predictors of progression (defined as a decline in FVC ⩾15%, or a relative decline in FVC of ⩾10%
together with a relative decline in DLCO ⩾15%) in patients with mild SSc-ILD (diagnosed by HRCT).
However, combining both predictors (SPO2 and ARthritis) increased the prediction rate from 25.5% to
91.7% [80]. In another study, a combination of smoking history, age and DLCO% pred was used to predict
risk of mortality [81] (interestingly, smoking alone has not been associated with a more rapid FVC decline
in SSc) [82]. These studies suggest that composite measures and staging systems could be used in clinical
practice to help discuss prognosis and guide clinical management. However, there is a risk that such
staging systems may lead physicians to withhold treatment in patients with “less advanced” disease who
may still be at risk of adverse outcomes [30].
Biomarkers
Reliable biomarkers could help to risk stratify patients. CC-chemokine ligand 18 (CCL18) and Krebs von
den Lungen-6 (KL-6) have shown potential predictive value for the progression of SSc-ILD [83, 84]. High
CCL18 serum levels were associated with a three-fold increased risk of a >10% decrease in FVC [83]. In a
study of patients with SSc, KL-6 was highest in those with extensive ILD and lowest in those without
TABLE 2 Risk factors for mortality and disease progression in systemic sclerosis-associated interstitial lung disease (SSc-ILD)
First author [ref.] Study design and patient numbers Independent risk factor(s) Measure of progression
STEEN [73] Analysis of 890 patients evaluated in a
US centre between 1972 and 1989
Disease severity (FVC % pred) 10-year cumulative survival
TYNDALL [4] Analysis of data from 2940 patients in
the EUSTAR database
FVC <80% pred and DLCO <80% pred Mortality
ZHANG [74] Analysis of 1043 patients from the
Canadian Scleroderma Research Group
(multicentre database)
Symptoms of oesophageal dysmotility Low FVC (<70%)
AHMED [75] Observational cohort of 188 patients
form the Toronto Scleroderma
Programme
Baseline FVC pred <70% and DLCO pred
<77%, higher age at baseline (adjusted for
FVC and DLCO)
Mortality
NIHTYANOVA [71] Single-centre cohort of 398 consecutive
patients with SSc followed for up to
15 years
Higher age at onset, dcSSc, lower FVC and
DLCO, presence of anti-topoisomerase I
antibodies
Clinically significant pulmonary
fibrosis (FVC or DLCO <55% pred
or documented decline in FVC
or DLCO <15%)
RYERSON [76] Application of four risk-prediction
models (derived from IPF) to 156
patients recruited from a specialised
SSc-ILD clinic
Baseline FVC, 6-min walk distance 1-year mortality
OKAMOTO [77] Retrospective analysis of 35 patients
with SSc-ILD
Usual interstitial pattern on HRCT, higher
score for ground-glass attenuation with
traction bronchiectasis on HRCT
Mortality
ELHAI [5] Analysis of data from 11193 patients in
the EUSTAR database
ILD, DLCO <60% pred, FVC <70% pred Mortality
VOLKMANN [78] Long-term, follow-up analysis of
patients in SLS I and II (up to 12 years in
SLS I (median 8 years), n=158; up to
8 years in SLS II (median 4 years),
n=142)
Decline in FVC and DLCO over 24 months,
increased age, increased mRSS
Mortality
BECKER [79] Analysis of 706 patients with diffuse SSc
and 12 months of follow-up from the
EUSTAR database
Advanced age (>60 years), active digital
ulcer; lung fibrosis (FVC <60% or FVC
<70% with presence of fibrosis on HRCT),
muscle weakness, elevated C-reactive
protein
Disease progression#
HOFFMANN-VOLD [2] Prospective Norwegian cohort study of
815 patients with SSc
>25% fibrosis on HRCT Mortality
HOFFMANN-VOLD [30] Analysis of 826 patients with FVC
measures available at baseline and after
12 months from the EUSTAR database
Male sex, higher mRSS, presence of
gastro-oesophageal reflux disease at
baseline
FVC decline over a 5-year
period
FVC: forced vital capacity; EUSTAR: European Scleroderma Trials and Research; DLCO: diffusing capacity of the lungs for carbon monoxide;
dcSSc: diffuse cutaneous SSc; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; SLS: Scleroderma Lung Study;
mRSS: modified Rodnan skin score. #: new renal crisis, decrease of lung or heart function, new echocardiography-suspected pulmonary
hypertension or death.
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ILD [84]. In an analysis of patient data from SLS II, in which treatment effects were controlled for and the
progression of ILD systematically monitored using multiple FVC measurements, patients with higher
baseline KL-6 and CCL18 levels were more likely to progress despite therapy [85]. In a recent
meta-analysis of 10 studies focused on circulating biomarkers in connective tissue disease-associated ILDs
(eight of which included patients with SSc-ILD only), KL-6 was found to correlate most strongly with a
diagnosis of SSc-ILD (OR 21.86 (95% CI 5.07–94.24), p<0.001), followed by surfactant protein D (OR
13.24 (3.84–45.71), p<0.001) and CCL18 (OR 3.31 (1.25–8.77), p=0.016). Furthermore, CCL18 (OR 2.62
(1.71–4.03), p<0.001) and KL-6 (OR 1.80 (1.02–3.17), p=0.04) were found to have prognostic value in
terms of decline in FVC and/or mortality [86]. Another potential biomarker in SSc-ILD is exhaled nitric
oxide, a widely used, noninvasive marker of airway inflammation in asthma. In one study, patients with
SSc-ILD had significantly lower median conducting airway nitric oxide compared with control subjects
(p=0.04) [87]. However, despite research efforts to date, large, longitudinal studies are needed to enable
the translational use of biomarkers specific to SSc-ILD in routine clinical practice.
Implications for treatment
Disease progression in SSc-ILD is common but is generally slower than in IPF [88]. The variable nature of
SSc-ILD and the lack of robust predictive markers make it challenging to determine which patients are
likely to progress (more rapidly), and when is the optimal time to initiate therapy. Accurate risk
stratification using evidence of lung function impairment, extent of fibrosis on HRCT and other
parameters could help to inform treatment decisions. According to the criteria proposed by some experts
or used in observational studies to date, initiation of treatment for SSc-ILD could be discussed under any
of the following circumstances: 1) clear evidence of ILD on HRCT; 2) indeterminate evidence of ILD on
HRCT combined with lung function impairment (e.g. >10% fibrosis on HRCT combined with FVC <70%
pred) and/or poor prognostic factors, such as Scl-70 (though this is more controversial) and elevation of
inflammatory parameters such as CRP; 3) a significant and sustained decline in lung function (e.g. FVC
⩾10% or FVC 5% to <10% with DLCO ⩾15%, in the absence of pulmonary hypertension); or 4) clear
evidence of radiographic progression of ILD, as determined by follow-up HRCT (if available) [60, 89–92].
Screening and regular monitoring with HRCT and/or PFTs is critical for early identification of ILD in
patients with SSc and to be able to understand its disease course. Timely treatment with therapeutic agents
is important for preserving or slowing the decline in lung function in SSc-ILD, especially considering the
association between measurements of pulmonary function early in the disease course and long-term
survival outcomes. Waiting to cross the currently pre-specified thresholds of lung function most common
in the current literature (10% and 15% for FVC and DLCO, respectively) or waiting for a demonstration of
deterioration in lung function of FVC% pred <70% [60] before initiating treatment may result in a missed
opportunity to slow disease progression and eventually preserve lung function and tissue. However, it
remains unclear whether earlier treatment might be associated with the prevention of irreversible organ
damage. Furthermore, the natural variability in the disease course of SSc-ILD has the potential to affect
clinical interpretation, considering the recent finding that periods of apparent stability in lung function
may represent a natural, short-term plateau within a wider arc of decline, and may not accurately predict
mid- and long-term outcomes.
Despite a growing body of evidence, the available data sets that can be used to study the natural
progression of SSc-ILD are still limited. Future large-scale studies of patients with SSc-ILD would add to
our understanding of how the disease course of SSc-ILD differs between patients (in its overall pace, as
well as short-term and long-term patterns of stability and decline).
The latest set of European League Against Rheumatism guidelines, published in 2017 and drafted prior to
the publication of the SLS II and SENSCIS trials, provide no criteria for defining ILD progression [93]. An
updated set of guidelines with proposed criteria for progression to guide clinical management, and to
reflect the recent approvals of nintedanib for the treatment of SSc-ILD in the USA and Europe [50, 51],
would be welcome. Until then, in the absence of formalised guidelines, consensus statements such as those
published by a group of 27 Europe-based physicians with expertise in SSc-ILD may help to guide clinical
decision-making. These consensus statements include close monitoring (every 3–6 months) of patients
who are considered to have early, stable, or mild SSc-ILD, using HRCT, FVC, DLCO, exercise-induced
blood oxygen desaturation and/or deterioration of clinical symptoms [18]. The decision to initiate, change
or stop treatment should be based on a combination of the current disease state and speed of progression;
however, no pre-specified criteria for progression are given as part of these consensus statements [18].
Conclusions
The disease course of SSc-ILD is heterogeneous and variable, and different patterns have been observed in
different studies, including clinical trials [31, 37, 47, 48]. Disease progression is frequent in patients with
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SSc-ILD but usually occurs at a slower rate than in IPF [88]. The current evidence from observational cohorts
suggests that 20–30% of patients will develop a progressive disease course [8, 30], starting within the first few
years of disease onset and then progressing at a variable rate. Predicting which patients are most likely to
progress, and at what rate, remains a challenge. Further research into composite measures of prediction, as
well as biomarkers, should continue to be evaluated in future studies to inform risk stratification. A wider
range of longitudinal data from observational cohorts worldwide would also help to clarify the association
between baseline characteristics, disease progression and long-term mortality, with the aim of improving
the prognostic accuracy of composite scores based on parameters early in the disease course.
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